Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Individualised therapy in advanced urothelial cancer: Prime time?

Q&A and live discussion

Date

16 Oct 2020

Session

Individualised therapy in advanced urothelial cancer: Prime time?

Presenters

Alison Birtle

Authors

A. Birtle

Author affiliations

Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, PR2 9HT - Preston/GB

More

Resources

Login to access the resources on OncologyPRO.

Login

Resources from the same session

16 Oct 2020

Molecular characterisation of urothelial cancer

Presenter: Holger Moch

Session: Individualised therapy in advanced urothelial cancer: Prime time?

Resources:

Slides

Webcast

16 Oct 2020

Chemotherapy, immunotherapy or combinations: What is the best option in the face of new evidence?

Presenter: Alison Birtle

Session: Individualised therapy in advanced urothelial cancer: Prime time?

Resources:

Slides

Webcast

16 Oct 2020

What to do if immunotherapy fails?

Presenter: Aristotelis Bamias

Session: Individualised therapy in advanced urothelial cancer: Prime time?

Resources:

Slides

Webcast